Navigation Links
Derma Sciences Announces Date of Its Third Quarter 2009 Earnings Release and Conference Call
Date:11/6/2009

PRINCETON, N.J., Nov. 6 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (OTC Bulletin Board: DSCI), a provider of advanced wound care products, announced plans to release its third quarter 2009 results before market on Monday, November 16, 2009. The Company will hold a conference call that same day to discuss the results at 11:00 am EST. Interested parties should call (866) 788-0546 (domestic) or (857) 350-1684 (international), with passcode 81416481 to access the call. You may also access this call via the Internet at:

http://phx.corporate-ir.net/playerlink.zhtml?c=107533&s=wm&e=2539678

For those who are unavailable to listen to the live broadcast, a replay will be available through December 16, 2009 and can be accessed by dialing 888-286-8010 (domestic), and 617-801-6888 (international). The passcode is 43541503.

About Derma Sciences

Derma Sciences is a specialty medical device / pharmaceutical company focusing on advanced wound care. Its key product, MEDIHONEY®, is sold throughout the world by Derma Sciences and Comvita New Zealand -- the licensor of the patented honey-based technology -- and is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of wounds and burns, and was the focus of a positive large-scale randomized controlled trial on leg ulcers. Derma's recently FDA cleared BIOGUARD(TM) Barrier Dressing is the Company's latest new product entrant into the $14 billion global wound care market. The barrier technology was licensed from Quick-Med Technologies, Inc. in Q1 of 2007. Derma also has in development DSC127, a novel angiotensin analog for accelerated wound healing and scar reduction. DSC127 was licensed from the University of Southern California in Q4 of 2007. Patient enrollment for a Phase II study began in Q4 of 2008. Results from this study are expected to be submitted to the FDA in Q2 of 2010.

For more information about Derma Sciences, Inc., visit http://www.dermasciences.com.

    Contact:

        Derma Sciences, Inc.
        Edward J. Quilty
        Chairman and CEO
        equilty@dermasciences.com
        (609) 514-4744

        The Investor Relations Group
        212-825-3210
        Investor Relations:
        Jason Strominger
        Or
        Media Relations:
        Susan Morgenbesser

SOURCE Derma Sciences, Inc.


'/>"/>
SOURCE Derma Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Orange County Dermatologist Garners Outstanding Results With New Thermage CPT(R)
2. Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD
3. Derma Sciences Announces Multiple Clinical Presentations of MEDIHONEY(R) at Upcoming Major Wound Care Conference
4. Estrogen Getting Cool Reception From Dermatologists for Mixed Results in Improving Appearance of Skin
5. Accent on Aesthetics Plastic Surgery Medical Center Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler
6. BioCis Pharma Reports Positive Phase IIa Clinical Results in Atopic Dermatitis
7. Clinical Trial Results of Pollogens TriPollar(TM) Radio Frequency Technology published in the Journal of the European Academy of Dermatology and Venereology
8. Spotlight on Rosacea Advance - May Issue of Journal of Drugs in Dermatology Features Pyratine XR(TM) Clinical Study
9. Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
10. Galderma Announces Interim Data Relating to Sequential Treatment Regimen of Clobex(R) Spray Followed by Vectical(TM) Ointment in Managing Plaque Psoriasis
11. Emerging Therapies Could Help Ease The Chronic Symptoms of Atopic Dermatitis For Adults and Children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... WASHINGTON , May 26, 2016 ... Microspheres, Associated With Both Cost Savings and ... BTG plc (LSE: BTG), an international specialist healthcare ... data at the 21st Annual Meeting of ISPOR ... that treatment of hepatocellular carcinoma (HCC) using yttrium-90 ...
(Date:5/25/2016)... und GERMANTOWN, Maryland , May ... mit Therawis bedient dringenden ... QIAGEN N.V. (NASDAQ: QGEN ... eine Lizenz- und Entwicklungsvereinbarung mit Therawis Diagnostics GmbH ... Onkologie eingegangen zu sein. Ein erstes Projekt wird ...
(Date:5/25/2016)... 2016 As illustrated by the ... month, the numbers and momentum of cannabis in the ... the billions, more research and development push the sector ... of Legal Marijuana Markets Report  from from ArcView Market ... of the increase in sector is attributed to adult ...
Breaking Medicine Technology:
(Date:5/26/2016)... , ... May 26, 2016 , ... ... Degeneration” for the Foundation Fighting Blindness, Long Island Chapter on June 4, 2016, ... public. , Dr. Maisel, founder of Retina Group of New York , ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... In an effort to provide hair restoration ... to both Snapchat users and those who do not use the app. Dr. Mohebi, the ... new page, Dr. Mohebi Live . , Dr. Mohebi says, “The positive response ...
(Date:5/26/2016)... ... May 26, 2016 , ... Leadership ... solutions, today announced the organization has earned its ISO 13485 certification, indicating the ... compliant with all rules and policies associated with ISO quality standard 13485. ...
(Date:5/26/2016)... ... ... The Lung Institute has partnered with the Gulfcoast North Area ... at their clinic in downtown Tampa. The class is complimentary for the public. Register ... a free downloadable 4 Week Smoking Cessation Guide for those who are ...
(Date:5/26/2016)... ... May 26, 2016 , ... Nike Yoga Camps ... from daily practices, arts & crafts, discussions, and games all geared towards enhancing ... Evans have combined backgrounds in kids’ yoga, collegiate sport yoga instruction, and global ...
Breaking Medicine News(10 mins):